Chemomab Therapeutics earnings were -$13.4M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest CMMB earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$3.3M, up 12.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, CMMB reported annual earnings of -$13.9M, with -42.4% growth.
Chemomab Therapeutics Earnings Reports & History FAQ
What were Chemomab Therapeutics's earnings last quarter?
On CMMB's earnings call on Invalid Date, Chemomab Therapeutics (NASDAQ: CMMB) reported Q1 2025 earnings per share (EPS) of -$0.14, up 50% year over year. Total CMMB earnings for the quarter were -$3.32 million. In the same quarter last year, Chemomab Therapeutics's earnings per share (EPS) was -$0.28.
Is Chemomab Therapeutics profitable or losing money?
As of the last Chemomab Therapeutics earnings report, Chemomab Therapeutics is currently losing money. Chemomab Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$13.40 million, a 30.7% decrease year over year.
What was CMMB's earnings growth in the past year?
As of Chemomab Therapeutics's earnings date in Invalid Date, Chemomab Therapeutics's earnings has grown year over year. CMMB earnings in the past year totalled -$13.40 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.